Dapagliflozin: An emerging treatment option in type 2 diabetes

Expert Opinion on Investigational Drugs

Volumn 18, Issue 3, 2009, Pages 327-334

  Kipnes, Mark ^a  

^a Cetero Research   (United States)

Author keywords

Dapagliflozin; Diabetes; Hyperglycemia; SGLT2

Indexed keywords

3 (5 BENZOFURANYL) 1 [2 HYDROXY 6 [6 O (METHOXYCARBONYL) BETA DEXTRO GLUCOPYRANOSYL] 4 METHYLPHENYL] 1 PROPANONE; ANTIDIABETIC AGENT; ASP 1941; AVE 2268; BI 10773; BI 44847; DAPAGLIFLOZIN; DSP 3235; JNJ 2841754; JNJ 28431754; PLACEBO; R 7201; REMOGLIFLOZIN; SAR 7226; SERGLIFLOZIN; SODIUM GLUCOSE COTRANSPORTER 2; TA 7284; TS 033; UNCLASSIFIED DRUG; YM 543; 2 (3 (4 ETHOXYBENZYL) 4 CHLOROPHENYL) 6 HYDROXYMETHYLTETRAHYDRO 2H PYRAN 3,4,5 TRIOL; 2-(3-(4-ETHOXYBENZYL)-4-CHLOROPHENYL)-6-HYDROXYMETHYLTETRAHYDRO-2H-PYRAN-3,4,5-TRIOL; GLUCOSIDE;

CLINICAL TRIAL; CONSTIPATION; DIARRHEA; DRUG DOSE COMPARISON; DRUG MECHANISM; DRUG STRUCTURE; GENITAL TRACT INFECTION; GLUCOSE ABSORPTION; GLUCOSURIA; HEADACHE; HUMAN; KIDNEY TUBULE ABSORPTION; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; REVIEW; SIDE EFFECT; SODIUM EXCRETION; URINARY TRACT INFECTION; ANIMAL; CHEMISTRY; DRUG ANTAGONISM; DRUG DEVELOPMENT; DRUG TOLERANCE; METABOLISM;

ANIMALS; DIABETES MELLITUS, TYPE 2; DRUG DISCOVERY; DRUG TOLERANCE; GLUCOSIDES; HUMANS; SODIUM-GLUCOSE TRANSPORTER 2;

EID: 67449084943     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543780902766794     Document Type: Review

References (27)

1. World Health Organization. Definition, diagnosis and classification of diabetes mellitus and its complications: report of a WHO Consultation. Part 1. Diagnosis and classification of diabetes mellitus. Available from: http://www.who.int/diabetes/publications/ Definition%20and%20diagnosis%20of%20diabetes-new.pdf [Last accessed 13 August 2008]
2. UK Prospective Diabetes Study Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998;352:854-865
3. Holman RR, Paul SK, Bethel MA, et al. 10-year follow-up of intensive glucose control in type2 diabetes. N Engl J Med 2008;359:1577-89 • A 10-year follow-up of patients who received either conventional or intensive therapy for glucose control demonstrated that intensive therapy was associated with a long-lasting reduced risk of myocardial infarction and death from any cause.
4. The ACCORD Study Group. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008;358:2545-2559
5. Wajchenberg BL. Beta-cell failure in diabetes and preservation by clinical treatment. Endocr Rev 2007;28:187-218 (Pubitemid 46984834)
6. Gaede P, Lund-Andersen H, Parving HH, et al. Effect of a multifactorial intervention on mortality in type2 diabetes. N Engl J Med 2008;358:580-91 • Intensive intervention with multiple therapies reduced cardiovascular and all-cause mortality compared with conventional therapy in patients with type 2 diabetes and persistent microalbuminuria.
7. Hoerger TJ, Segel JE, Gregg EW, Saaddine JB. Is glycemic control improving in US adults? Diabetes Care 2008;31:81-86
8. Chen J, Feder J, Neuhaus I, Whaley JM. Tissue expression profiling of the sodium-glucose co-transporter (SGLT) family: Implication for targeting SGLT2 in type 2 diabetes patients [abstract #2493-PO]. American Diabetes Association, San Francisco, USA, 6-10 June 2008
9. Lee YJ, Lee YJ, Han HJ. Regulatory mechanisms of Na(+)/ glucose cotransporters in renal proximal tubule cells. Kidney Int Suppl 2007;106:S27-35 (Pubitemid 47172558)
10. Wood IS, Trayhurn P. Glucose transporters (GLUT and SGLT): expanded families of sugar transport proteins. Br J Nutr 2003;89:3-9 • Provides a detailed description of glucose transporters, including tissue and substrate specificity.
11. Zelikovic I. Aminoaciduria and glycosuria. Fifth edition. In: Avner ED, Harmon WE, Niaudet P, editors, Pediatric Nephrology. Philadelphia: Lippincott Williams & Wilkins, 2004. p. 701-728
12. Moe OW, Wright SH, Palacín M. Renal handling of organic solutes. Eighth edition. In: Brenner BM, editor, Brenner and Rector's The Kidney. Philadelphia: Saunders Elsevier, 2008
13. Oku A, Ueta K, Arakawa K, et al. T-1095, an inhibitor of renal Na+ glucose cotransporters, may provide a novel approach to treating diabetes. Diabetes 1999;48:1794-1800 (Pubitemid 29415199)
14. Meng W, Ellsworth BA, Nirschl AA, et al. Discovery of dapagliflozin: a potent, selective renal sodium-dependent glucose cotransporter 2 (SGLT2) inhibitor for the treatment of type2 diabetes. J Med Chem 2008;51:1145-1149
15. Ehrenkranz JRL, Lewis NG, Kahn CR, Roth J. Phlorizin: a review. Diabetes Metab Res Rev 2005;21:31-8 • This review describes the SGLT inhibitor phlorizin, including pharmacology, toxicology, and its investigational use in diabetes mellitus.
16. Scholl-Bürgi S, Santer R, Ehrich JH. Long-term outcome of renal glucosuria type 0: the original patient and his natural history. Nephrol Dial Transplant 2004;19:2394-2396 (Pubitemid 39214139)
17. Santer R, Kinner M, Lassen CL, et al. Molecular analysis of the SGLT2 gene in patients with renal glucosuria. J Am Soc Nephrol 2003;14:2873-2882 (Pubitemid 37305650)
18. Rossetti L, Smith D, Shulman GI, et al. Correction of hyperglycemia with phlorizin normalizes tissue sensitivity to insulin in diabetic rats. J Clin Invest 1987;79:1510-1515 (Pubitemid 17099657)
19. Han S, Hagan DL, Taylor JR, et al. Dapagliflozin, a selective SGLT2 inhibitor, improves glucose homeostasis in normal and diabetic rats. Diabetes 2008;57:1723-1729
20. Devenny J, Harvey S, Rooney S, et al. The effect of dapagliflozin (BMS-512148), a selective SGLT2 inhibitor, on body weight in diet-induced obese rats [abstract #384]. North american association for the study of obesity, New Orleans, 22 October 2007
21. Komoroski B, Vachharajani N, Boulton D, et al. Dapagliflozin, a novel SGLT2 inhibitor, induces dose-dependent glucosuria in healthy subjects. Clin Pharmacol Ther 2009 [Epub 7 Jan 2009]
22. Komoroski B, Vachharajani N, Feng Y, et al. Dapagliflozin, a novel, selective SGLT2 inhibitor, improved glycemic control over 2 weeks in patients with type2 diabetes mellitus. Clin Pharmacol Ther 2009 [Epub 7 Jan 2009] •• A Phase IIa clinical trial of dapagliflozin in patients with type 2 diabetes showing that dapagliflozin dose-dependently increased urinary glucose excretion and improved glycemic parameters.
23. List J, Woo V, Morales E, et al. Sodium-glucose co-transport inhibition with dapagliflozin in type 2 diabetes mellitus. Diabetes Care 2008 [Epub 29 Dec 2008] •• A Phase IIb clinical trial of dapagliflozin showing improved hyperglycemia and reduced body weight following 12 weeks of dapagliflozin treatment in patients with type 2 diabetes.
24. Isaji M. Sodium-glucose cotransporter inhibitors for diabetes. Curr Opin Investig Drugs 2007;8:285-92 • A comprehensive review of the SGLT inhibitors, including their development for diabetes, pharmacology and potential benefits.
25. Oku A, Ueta K, Arakawa K, et al. T-1095, and inhibitor of renal Na+-glucose cotransporters, may provide a novel approach to treating diabetes. Diabetes 1999;48:1794-1800 (Pubitemid 29415199)
26. Hussey E, Clark R, Amin DM, Kipnes M et al. Early clinical studies to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of single doses of sergliflozin, a novel inhibitor of renal glucose reabsorption, in healthy volunteers and subjects with type 2 diabetes mellitus (Abstract 189-OR). 67th Annual Meeting of the American Diabetes Association, 22-26 June, 2007; Chicago, IL, USA
27. Harrington WW, Milliken NO, Binz JG, et al. Remogliflozin etabonate, a potent and selective sodium-dependent glucose transporter 2 antagonist, produced sustained metabolic effects in Zucker diabetic fatty rats [abstract #529-P]. American Diabetes Association, San Francisco, 6-10 June 2008